You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1345 mTFF2-MSA (mTNX-1700) suppresses tumor growth and increases survival in anti-PD-1 treated CT26.wt subcutaneous and CT26-Luciferase orthotopic syngeneic colorectal cancer models by targeting MDSCs

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1345 mTFF2-MSA (mTNX-1700) suppresses tumor growth and increases survival in anti-PD-1 treated CT26.wt subcutaneous and CT26-Luciferase orthotopic syngeneic colorectal cancer models by targeting MDSCs

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Daugherty BL, Boohaker RJ, Johnstone R, et al
1345 mTFF2-MSA (mTNX-1700) suppresses tumor growth and increases survival in anti-PD-1 treated CT26.wt subcutaneous and CT26-Luciferase orthotopic syngeneic colorectal cancer models by targeting MDSCs
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1345